You are here

FDA Lifts Hold on Studies of Cancer Drug Tosedostat

Agency requested data on heart-related events (January 2)

Cell Therapeutics, Inc. has announced that it has received notification from the FDA that the partial clinical hold on tosedostat (IND 075503) has been removed and that all studies underway may continue.

The FDA placed the hold after a patient treated with a combination of tosedostat and a chemotherapy drug died of a heart-muscle infection. The agency requested more information on all heart-related events in patients treated with tosedostat.

Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. The drug is under development for the treatment of blood-related cancers. It is currently being studied in the U.S. and Europe in phase II trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) or with high-risk myelodysplastic syndrome (MDS).

Sources: Cell Therapeutics, Inc.; January 2, 2014; and Reuters; January 2, 2014.

Recent Headlines

Superior to Quinine in Reducing Mortality in Two Clinical Trials
Minimally Invasive Method Reduces Regurgitation and Leaking
Neurofilament Light Protein Correlated With Accumulated Brain Damage
Technology Designed to Improve Patient Care, Limit Infections
Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Possible First Treatment Option for Rare Autoimmune Disease of the CNS